Allergan (AGN) Says Pivotal Trials for OCUN-009 and OCUN-010 Met Primary, Secondary Endpoints
Tweet Send to a Friend
Allergan plc (NYSE: AGN) announced that two pivotal trials of the Oculeve Intranasal Tear Neurostimulator, OCUN-009 and OCUN-010, each met ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
